Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

  title={Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.},
  author={Andrew Menzies-Gow and Jonathan Corren and Arnaud Bourdin and Geoffrey Lowell Chupp and Elliot Israel and Michael E. Wechsler and Christopher E. Brightling and Janet M. Griffiths and {\AA}sa Hellqvist and Karin Bowen and Primal P. Kaur and Gun Almqvist and Sandhia Ponnarambil and Gene L. Colice},
  journal={The New England journal of medicine},
  volume={384 19},
BACKGROUND Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment. METHODS We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Patients (12 to 80 years of age) were randomly assigned to receive tezepelumab (210 mg) or placebo subcutaneously… 
Tezepelumab: First Approval
The milestones in the development of tezepelumab leading to this first approval for the add-on maintenance treatment of patients aged ≥ 12 years with severe asthma are summarized.
Comparative Efficacy and Safety of Tezepelumab and Other Biologics in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis
A network meta-analysis to compare and rank the efficacy of five treatments for asthma in overall participants and in subgroups stratified by the thresholds of type 2 inflammatory biomarkers provided a basis for the development of treatment strategies for asthma.
The choice of biologics in patients with severe chronic rhinosinusitis with nasal polyps.
Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
The aim of the study is to review the immunopathology and treatment efficacy for severe asthma and focused on new biological agents with benralizumab (anti-IL-5) and tezepelumab(anti-TSLP).
Emerging treatments for chronic urticaria
  • B. Wedi
  • Biology, Medicine
    Expert opinion on investigational drugs
  • 2022
The pipeline, namely anti-IgE-, anti-cytokine, anti-receptor biologics, and small molecules, in clinical development for CU are explored, finding the pipeline is promising and as the pipeline addresses different targets, study results will give deeper insights into the pathomechanisms of CU.
Biologics in Asthma: A Molecular Perspective to Precision Medicine
The immunology of asthma, the cytokines or receptors currently targeted, the possible mechanisms of sub-optimal responses, and the importance of determining the immune make-up of individual patients prior to prescribing mAb therapy, in the age of precision medicine for asthma are summarized.
Biologics in the Treatment of Severe Uncontrolled Asthma in Children
  • N. Syabbalo
  • Medicine, Biology
    Journal of Thoracic Disease and Cardiothoracic Surgery
  • 2021
Most of the children with asthma respond to low and medium inhaled corticosteroids, however a significant proportion still have severe asthma uncontrolled on the standard of care, and ILAs have been demonstrated to improve the health-related quality of life, and have steroid sparing effect.
Anti-Interleukin Biologics for the treatment of the Atopic March Diseases
In patients with eosinophilic asthma treatment with dupilumab has been shown to improve asthma control, reduce exacerbations, and improve lung function, and the Peak Pruritus Numerical Rating (PNR) scale.